Ann: MND Trial Completes Enrolment of Cohort 2, page-38

Hi Buckland and Paralogical,

Is this your query. Remember SOD1 in MND patients occur 3% of the total MND population.


Conclusions: In persons with SOD1 ALS, tofersen reduced concentrations of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks but did not improve clinical end points and was associated with adverse events. The potential effects of earlier as compared with delayed initiation of tofersen are being further evaluated in the extension phase. (Funded by Biogen; VALOR and OLE ClinicalTrials.gov numbers, NCT02623699 and NCT03070119; EudraCT numbers, 2015-004098-33 and 2016-003225-41

Cheers

Kpax